1型糖尿病合并治疗抵抗性难控性低血糖成人的特征:HARPdoc随机对照试验的基线分析
本研究为HARPdoc随机对照试验的横断面基线分析,纳入99例接受灵活胰岛素治疗结构化教育后仍存在难控性低血糖的1型糖尿病成人,评估其情绪、认知和行为特征。受试者焦虑和抑郁水平较高,多数存在对低血糖的不利健康信念且低血糖恐惧较低,并可分为两个不同特征的聚类;与倾向匹配的对照人群相比,对照组焦虑和抑郁评分显著更低。
要点
- HARPdoc队列糖尿病病程长(均值±标准差35.8±15.4年),Gold评分均值±标准差5.3±1.2。
- 过去一年严重低血糖事件中位数(四分位距)为5.0(2.0-12.0)次。
- 49.5%受试者焦虑筛查阳性,35.0%抑郁筛查阳性,31.3%存在高度糖尿病痛苦。
核心结论
- HARPdoc方案成功招募了治疗抵抗性难控性低血糖患者,该人群焦虑和抑郁水平较高。
- 多数受试者存在对低血糖的不利健康信念且低血糖恐惧较低,这一组合可能促成难控性低血糖的持续存在,并可能成为辅助心理治疗的目标。
研究设计与样本
- HARPdoc试验的横断面基线描述性分析,纳入99例接受灵活胰岛素治疗结构化教育后仍存在难控性低血糖的1型糖尿病成人。
- 采用低血糖恐惧调查表II(HFS-II)、低血糖意识态度问卷(A2A)、医院焦虑抑郁量表及糖尿病问题区域量表进行评估,并对HFS-II和A2A因子进行k均值聚类分析。
- 数据与按年龄、性别和糖尿病病程倾向匹配的无难控性低血糖的同伴组(n=81)进行比较。
主要发现
- HARPdoc队列糖尿病病程均值±标准差为35.8±15.4年,Gold评分均值±标准差为5.3±1.2,过去一年严重低血糖事件中位数(四分位距)为5.0(2.0-12.0)次。
- 多数个体曾被提供技术手段,49.5%焦虑筛查阳性(35.0%抑郁筛查阳性,31.3%存在高度糖尿病痛苦)。
- 队列分为两个聚类:一簇(n=68)认同A2A认知障碍妨碍低血糖规避,HFS-II因子恐惧较低;另一簇(n=29)A2A因子评分低而HFS-II评分高。
- 对照组的焦虑和抑郁评分显著低于HARPdoc队列。
关键数值与推荐
- HARPdoc队列的Gold评分均值±标准差为5.3±1.2。
- 过去一年严重低血糖事件中位数(四分位距)为5.0(2.0-12.0)次。
- 焦虑筛查阳性比例为49.5%,抑郁筛查阳性比例为35.0%,高度糖尿病痛苦比例为31.3%。
- 聚类一(n=68)特征为A2A认知障碍得分高且HFS-II恐惧因子得分低;聚类二(n=29)特征为A2A因子得分低且HFS-II得分高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Problematic hypoglycaemia still complicates insulin therapy for some with type 1 diabetes. This study describes baseline emotional, cognitive and behavioural characteristics in participants in the HARPdoc trial, which evaluates a novel intervention for treatment-resistant problematic hypoglycaemia. METHODS: We documented a cross-sectional baseline description of 99 adults with type 1 diabetes and problematic hypoglycaemia despite structured education in flexible insulin therapy. The following measures were included: Hypoglycaemia Fear Survey II (HFS-II); Attitudes to Awareness of Hypoglycaemia questionnaire (A2A); Hospital Anxiety and Depression Index; and Problem Areas In Diabetes. k-mean cluster analysis was applied to HFS-II and A2A factors. Data were compared with a peer group without problematic hypoglycaemia, propensity-matched for age, sex and diabetes duration (n = 81). RESULTS: The HARPdoc cohort had long-duration diabetes (mean ± SD 35.8 ± 15.4 years), mean ± SD Gold score 5.3 ± 1.2 and a median (IQR) of 5.0 (2.0-12.0) severe hypoglycaemia episodes in the previous year. Most individuals had been offered technology and 49.5% screened positive for anxiety (35.0% for depression and 31.3% for high diabetes distress). The cohort segregated into two clusters: in one (n = 68), people endorsed A2A cognitive barriers to hypoglycaemia avoidance, with low fear on HFS-II factors; in the other (n = 29), A2A factor scores were low and HFS-II high. Anxiety and depression scores were significantly lower in the comparator group. CONCLUSIONS/INTERPRETATION: The HARPdoc protocol successfully recruited people with treatment-resistant problematic hypoglycaemia. The participants had high anxiety and depression. Most of the cohort endorsed unhelpful health beliefs around hypoglycaemia, with low fear of hypoglycaemia, a combination that may contribute to persistence of problematic hypoglycaemia and may be a target for adjunctive psychological therapies.
引用
- Jacob P, Potts L, Maclean RH, et al. Characteristics of adults with type 1 diabetes and treatment-resistant problematic hypoglycaemia: a baseline analysis from the HARPdoc RCT. Diabetologia. 2022. PMID: 35325258. doi:10.1007/s00125-022-05679-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。